FK506 binding protein 12.6-mediated inhibition of sperm-specific calcineurin is essential for FK506-induced male infertility by disturbing the homeostasis of calcium and mitochondria.
Saved in:
| Title: | FK506 binding protein 12.6-mediated inhibition of sperm-specific calcineurin is essential for FK506-induced male infertility by disturbing the homeostasis of calcium and mitochondria. |
|---|---|
| Authors: | Xiao YF; National Engineering Research Center for Bioengineering Drugs and the Technologies, Institute of Translational Medicine, Jiangxi Medical College, Nanchang University, Nanchang, People's Republic of China. xyf.84@163.com.; Jiangxi Province Key Laboratory of Bioengineering Drugs, Institute of Translational Medicine, Nanchang, People's Republic of China. xyf.84@163.com., Yang SF; National Engineering Research Center for Bioengineering Drugs and the Technologies, Institute of Translational Medicine, Jiangxi Medical College, Nanchang University, Nanchang, People's Republic of China.; Jiangxi Province Key Laboratory of Bioengineering Drugs, Institute of Translational Medicine, Nanchang, People's Republic of China.; School of Pharmacy, Jiangxi Medical College, Nanchang University, Nanchang, 330031, People's Republic of China., Huang SA; National Engineering Research Center for Bioengineering Drugs and the Technologies, Institute of Translational Medicine, Jiangxi Medical College, Nanchang University, Nanchang, People's Republic of China.; Jiangxi Province Key Laboratory of Bioengineering Drugs, Institute of Translational Medicine, Nanchang, People's Republic of China.; School of Pharmacy, Jiangxi Medical College, Nanchang University, Nanchang, 330031, People's Republic of China., Zeng ZX; National Engineering Research Center for Bioengineering Drugs and the Technologies, Institute of Translational Medicine, Jiangxi Medical College, Nanchang University, Nanchang, People's Republic of China., Gong LN; National Engineering Research Center for Bioengineering Drugs and the Technologies, Institute of Translational Medicine, Jiangxi Medical College, Nanchang University, Nanchang, People's Republic of China., Xie L; National Engineering Research Center for Bioengineering Drugs and the Technologies, Institute of Translational Medicine, Jiangxi Medical College, Nanchang University, Nanchang, People's Republic of China.; Jiangxi Provincial People's Hospital, the First Affiliated Hospital of Nanchang Medical College, Nanchang, 330031, People's Republic of China., Wang LF; National Engineering Research Center for Bioengineering Drugs and the Technologies, Institute of Translational Medicine, Jiangxi Medical College, Nanchang University, Nanchang, People's Republic of China.; Jiangxi Province Key Laboratory of Bioengineering Drugs, Institute of Translational Medicine, Nanchang, People's Republic of China., Guan XH; National Engineering Research Center for Bioengineering Drugs and the Technologies, Institute of Translational Medicine, Jiangxi Medical College, Nanchang University, Nanchang, People's Republic of China.; Jiangxi Province Key Laboratory of Bioengineering Drugs, Institute of Translational Medicine, Nanchang, People's Republic of China., Jiang MX; National Engineering Research Center for Bioengineering Drugs and the Technologies, Institute of Translational Medicine, Jiangxi Medical College, Nanchang University, Nanchang, People's Republic of China.; Jiangxi Province Key Laboratory of Bioengineering Drugs, Institute of Translational Medicine, Nanchang, People's Republic of China., Qian YS; National Engineering Research Center for Bioengineering Drugs and the Technologies, Institute of Translational Medicine, Jiangxi Medical College, Nanchang University, Nanchang, People's Republic of China.; Jiangxi Province Key Laboratory of Bioengineering Drugs, Institute of Translational Medicine, Nanchang, People's Republic of China., Deng KY; National Engineering Research Center for Bioengineering Drugs and the Technologies, Institute of Translational Medicine, Jiangxi Medical College, Nanchang University, Nanchang, People's Republic of China. dky@ncu.edu.cn.; Jiangxi Province Key Laboratory of Bioengineering Drugs, Institute of Translational Medicine, Nanchang, People's Republic of China. dky@ncu.edu.cn.; School of Pharmacy, Jiangxi Medical College, Nanchang University, Nanchang, 330031, People's Republic of China. dky@ncu.edu.cn., Xin HB; National Engineering Research Center for Bioengineering Drugs and the Technologies, Institute of Translational Medicine, Jiangxi Medical College, Nanchang University, Nanchang, People's Republic of China. xinhb@ncu.edu.cn.; Jiangxi Province Key Laboratory of Bioengineering Drugs, Institute of Translational Medicine, Nanchang, People's Republic of China. xinhb@ncu.edu.cn.; School of Pharmacy, Jiangxi Medical College, Nanchang University, Nanchang, 330031, People's Republic of China. xinhb@ncu.edu.cn. |
| Source: | Molecular biomedicine [Mol Biomed] 2025 Dec 22; Vol. 6 (1), pp. 149. Date of Electronic Publication: 2025 Dec 22. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Springer Singapore Country of Publication: Singapore NLM ID: 9918283581406676 Publication Model: Electronic Cited Medium: Internet ISSN: 2662-8651 (Electronic) Linking ISSN: 26628651 NLM ISO Abbreviation: Mol Biomed Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
